SCHEMBL17330726

SCHEMBL17330726

CC(C)(C)OC(=O)N1CCN(n2c(C(N)C3CC3)nc3c(F)ccc(F)c3c2=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.41
PIK3CD O00329 5/20 0.41
PIK3R2 O00459 3/20 0.41
CYP3A4 P08684 2/20 0.40
CYP3A5 P20815 2/20 0.40
GPR119 Q8TDV5 5/20 0.38
TRPV3 Q8NET8 1/20 0.38
MAPT P10636 2/20 0.36
CNR1 P21554 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR35 Q9HC97 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17330727 1.00 DPP4 (0.41) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330853 0.93 PIK3R2 (0.43) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330851 0.93 PIK3R2 (0.43) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330621 0.89 PIK3CD (0.41) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330622 0.89 PIK3CD (0.41) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17338269 0.85 PIK3CD (0.45) PIK3CDPIK3R2
SCHEMBL17330919 0.82 PIK3CD (0.46) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330920 0.82 PIK3CD (0.46) DPP4PIK3CDPIK3R2CYP3A4CYP3A5
SCHEMBL17330706 0.80 PIK3CD (0.45) PIK3CDPIK3R2
SCHEMBL17330708 0.80 PIK3CD (0.45) PIK3CDPIK3R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154958-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES INC (US) 2020-10-07 EP disclosed
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-10-09 US disclosed
EP-3154958-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Gilead Sciences, Inc. (US) 2017-04-19 EP disclosed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
WO-2015191752-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PIK3CA, AKT3, PIK3CB DPP4 3545/4885PIK3CD 5/4885PIK3R2 22/4885
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors PIK3CA, AKT3, PIK3CB DPP4 3545/4885PIK3CD 5/4885PIK3R2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.